1. Home
  2. Directory
  3. California
  4. San Francisco
  5. Radiology
  6. NPI Profile
  7. Prescriptions 1235540469

DR. JULIAN C HONG M.D., M.S.
Prescription History 1235540469
Radiology - Radiation Oncology in San Francisco, CA


Quality Rating: 74.46 out of 100 score

NPI Status: Active since May 09, 2014

Contact Information

1825 4TH ST RM M2260
SAN FRANCISCO, CA
ZIP 94143
Phone: (415) 502-7222

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. JULIAN C HONG M.D., M.S., an active Radiation Oncology specialist practicing in San Francisco, CA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 151 documented patient claims. Among these therapy options, the most frequently utilized medication is Terazosin Hcl, which accounts for 63 claims alone.

Medication Index

M
O
T
No matching medications currently found on file.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 13.0
Days Supply 390
CA State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills79.8
Peer Average Days Supply2,333
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.5% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,136.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$511.41

State Avg Cost Per Claim

$683.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Oxybutynin Chloride Er

Generic Formulation: Oxybutynin ChlorideSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 27
30-Day Fills 42.5
Days Supply 1,244
CA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills59.9
Peer Average Days Supply1,768
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $927.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.36

State Avg Cost Per Claim

$45.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This is a long-acting form of oxybutynin that is used to treat overactive bladder and urinary conditions. It relaxes the muscles in the bladder to help decrease problems of urgency and frequent urination. Oxybutynin belongs to a class of drugs known as antispasmodics. This medication is also used to treat children 6 years of age and older who have an overactive bladder due to certain nerve disorders (such as spina bifida).

Tamsulosin Hcl

Generic Formulation: Tamsulosin HclSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 49
30-Day Fills 95.3
Days Supply 2,845
CA State Average Benchmarks
Peer Average Claims80.0
Peer Average 30-Day Fills186.7
Peer Average Days Supply5,536
Conservative Utilization

This provider writes prescriptions for this formulation 38.8% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $737.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.06

State Avg Cost Per Claim

$19.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tamsulosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tamsulosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Terazosin Hcl

Generic Formulation: Terazosin HclSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 63
30-Day Fills 86.0
Days Supply 2,215
CA State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills101.6
Peer Average Days Supply3,026
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 75.0% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,508.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.94

State Avg Cost Per Claim

$40.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Terazosin is used alone or with other drugs to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This medication works by relaxing blood vessels so blood can flow more easily. Terazosin is also used in men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and part of the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate frequently or urgently (including during the middle of the night). Terazosin belongs to a class of drugs known as alpha blockers.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. JULIAN C HONG M.D., M.S. provides transparency into local medical care patterns within San Francisco, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Radiation Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.